Kymera reports Q1 net loss $69.2M; Gilead licenses KT-200 for $45M milestone

Kymera Therapeutics, Inc.

2026-Q1 EPS reported -$0.71 revenue$34,365,000

Net loss $69.2M in Q1 2026, vs $65.6M in Q1 2025; cash $1.55B provides runway into 2029.
Collaboration revenue $34.4M (all from Gilead), up from $22.1M in Q1 2025.
Gilead exercised option to license KT-200 (oral CDK2 degrader), triggering a $45M milestone payment.
KT-621 Phase 2b BROADEN2 (AD) data expected mid-2027; BREADTH (asthma) data late 2027; FDA Fast Track for asthma.
KT-579 Phase 1 healthy volunteer trial ongoing; data expected in 2H26; KT-485/SAR447971 IND complete, clinical entry 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Kymera Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On April 30, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.

View on SEC.gov

1431 earnings releases filed in the last 30 days. Browse all earnings releases →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-193957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.